Dose-Escalation Study Evaluating Pegylated Interferon Alpha-2a in Patients with Cutaneous T-Cell Lymphoma

Abstract

Background

This open-label, multicenter, dose-escalation study evaluated the safety, tolerability, and efficacy of subcutaneous pegylated (40 kD) interferon α-2a (PEG-IFN α-2a) in patients with cutaneous T-cell lymphoma (CTCL).

Patients and Methods

PEG-IFNα-2a was administered subcutaneously at 180 (n=4), 270 (n=6), or 360 μg (n=3) once weekly for 12 weeks. Efficacy was assessed by the proportion of patients with complete response (CR) or partial response (PR).

Results

PEG-IFNα-2a was generally well tolerated, with a moderate number of reductions or withholding of doses because of adverse events (25% (n=1), 66% (n=4), and 0% (n=0) in the 180, 270, and 360-μg/week groups, respectively). The only dose-limiting toxicity was a grade 3 elevation of liver enzymes in the 270μg dose group. The most common adverse events were fatigue, acute flu-like symptoms, and hepatic toxicity. The major response rate (CR or PR) was 50% in the 180-μg group (CR, 50%; PR, 0%), 83% in the 270-μg group (CR, 67%; PR, 17%), and 66% in the 360-μg group (CR, 33%; PR, 33%).

Conclusion

PEG-IFNα-2a at doses up to 360 μg once weekly was well tolerated in patients with CTCL up to the highest dose group and showed good response rates. Due to their good tolerance even in high doses they might be an option for patients not toleratingstandard IFNα preparations. However, for this purpose and to evaluate comparability between standard and PEG-IFN larger clinical trials are needed, alone and in combination with oral photochemotherapy (PUVA).

This article is protected by copyright. All rights reserved.

http://ift.tt/2qwDVeD